期刊文献+

568例HER2不确定乳腺癌原位杂交结果分析 被引量:6

In Situ Hybridization Status of 568 Cases of HER2 Equivocal Breast Cancer
下载PDF
导出
摘要 目的比较2013版及2018版美国临床肿瘤学会/美国病理医师学院(ASCO/CAP)乳腺癌HER2检测指南,对免疫组织化学HER2不确定(2+)乳腺癌FISH判读结果的影响及其临床意义。通过与FISH对比,分析DISH的准确性及存在问题。方法选取568例免疫组织化学HER2不确定浸润性乳腺癌石蜡包埋标本,使用FISH技术进行HER2基因状态检测,分别采用2013及2018版ASCO/CAP乳腺癌HER2检测指南进行结果判读。随机选取60例样本进行DISH检测,并与FISH对比分析。结果依据2013版指南,HER2阳性183例(32.22%)、阴性365例(64.26%)、不确定20例(3.52%)。采用新指南判读标准,HER2阳性率减少了4.58%,阴性率无差别,两种判读标准差异具有统计学意义(P<0.01)。对60例肿瘤样本的FISH和DISH检测结果比较,两者总符合率为95.0%,阳性符合率为94.7%;阴性符合率为100%,两种方法的检测结果显著相关(r=0.636, P<0.01)。结论 2018版ASCO/CAPHER2检测指南与2013版相比,判读标准更明确、分类更精细,对临床用药更具指导作用。DISH技术具有亮视野的优点,与FISH有同样的临床诊断价值。 Objective To compare the differences between 2013 and 2018 ASCO/CAP HER2 testing guidelines in 568 immunohistochemical HER2 equivocal breast cancer patients and to analyze the accuracy and deficiency of dual-color silver enhanced in-situ hybridization(DISH) by comparing with FISH. Methods We selected 568 cases of paraffin-embedded invasive breast cancer specimen which were proved as HER2 equivocal by immunohistochemical(IHC). The HER2 gene amplification status was evaluated by FISH and comparatively analyzed according to both the 2013 and 2018 ASCO/CAP HER2 Testing guidelines respectively. Sixty specimens were randomly selected for DISH detection and compared with FISH. Results According to the 2013 guideline, the number of HER2 positive, negative and equivocal cases were 183(32.22%), 365(64.26%) and 20(53.52%), respectively. Compared with the 2013 guideline, HER2 positive rate decreased by 4.58% according to the revised 2018 guideline, and the negative rates were same;the difference of positive rates was statistically significant(P<0.01). Comparison between FISH and DISH findings in 60 samples, the total, positive and negative coincidence rates were 95.0%, 94.7% and 100%, and the results of the two methods are significantly correlated(r=0.636, P<0.01). Conclusion Compared with 2013 ASCO/CAP guideline, the revised 2018 guidelines is more accurate and instructive for clinical medication. DISH could achieve similar precise results as compared to FISH. Bright field detection is the irreplaceable advantage of DISH.
作者 蒋依娜 王博 周灿 王鸿雁 JIANG Yi’na;WANG Bo;ZHOU Can;WANG Hongyan(Department of Pathology,The First Affiliated Hospital of Xi’an Jiao Tong University,Xi’an 710061,China)
出处 《肿瘤防治研究》 CAS CSCD 2019年第7期605-609,共5页 Cancer Research on Prevention and Treatment
基金 国家自然科学基金(81502413)
关键词 荧光原位杂交 双色银增强原位杂交 人表皮生长因子受体2 乳腺癌 曲妥珠单抗 Fluorescent in situ hybridization Dual-color silver enhanced in-situ hybridization HER2 Breast cancer Trastuzumab
  • 相关文献

参考文献2

二级参考文献24

  • 1张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer [ J]. J Clin Oncol, 2007, 25 (33) :5287-5312.
  • 4Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Chnical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[ Jl. J Clin Oncol, 2007, 25 ( 1 ) : 118- 145.
  • 5Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth faetor reeeptor 2 testing in breast eaneer: American Society of Clinical Oneology/College of American Pathologists clinical practice guideline update[J]. J Clin Oneol, 2013, 31 (31) :3997-4013.
  • 6Hanna WM, Kwok K. Chromogenic in-situ hybridization:a viable ahernative to fluorescence in-situ hybridization in the HER2 testing algorithm[J]. Mod Pathol, 2006, 19(4) :481-487.
  • 7Park K, Han S, Kim JY, et al. Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer [ J ]. J Breast Cancer, 2011, 14(4) :276-282.
  • 8Haines GK 3rd, Wiley E, Susnik B, et al. HER2 in well differentiated breast cancer: is testing necessary? [ J ]. Breast Cancer Res Treat, 2008, 112(3) :551-556.
  • 9Zhu X, Lu Y, Lu H, et al. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer [J]. Hum Pathol, 2011,42(10) : 1499-1504.
  • 10Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer.9 A fluorescence in situ hybridization and microarray-based CGH analysis[ J]. J Pathol, 2009, 219( 1 ) : 16-24.

共引文献547

同被引文献65

引证文献6

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部